Cashu
Mind Medicine (MNMD) Advances Innovative Treatments for Brain Health Disorders at Oppenheimer Conference
7 months ago
Stocks
Health Care
mnmd
Mind Medicine
NASDAQ: MNMD
+0.24 (+2.76%)
9.125
USD
At close at Sep 02, 20:45 UTC
Overview
Loading chart...
Key Stats
Market Cap
670.91M
Dividend Yield
0.00%
P/E Ratio
-5.86
EPS
-0.94
Revenue
-
Avg. Volume
1.45M
About
What does MNMD do?
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company based in New York, focused on developing novel treatments for brain health disorders, including MM-120 for anxiety and ADHD, and MM-402 for autism. Founded in 2015, the company employs 57 people and targets neurotransmitter pathways using psychedelics and empathogens.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.